A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845

Phase 1

Completed

• Conditions: Hypogonadism
• Interventions: Drug: D309; Drug: CKD-845

• Registration Number: NCT04673682
• Lead Sponsor: Chong Kun Dang Pharmaceutical

Brief Summary

A clinical trial to evaluate the pharmacokinetic profiles and safety of CKD-845.

Detailed Description

A phase 1 clinical trial to evaluate pharmacokinetics and safety in male after administration of CKD-845 and D309.

Study Timeline

• Study First Submitted: 2020-11-06
• Study Start: 2020-11-16
• Study First Submitted QC: 2020-12-16
• Study First Posted: 2020-12-17
• Primary Completion: 2022-05-17
• Study Completion: 2022-06-07
• Status Verified: 2022-09
• Last Update Submitted: 2022-09-26
• Last Update Posted: 2022-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 47

Inclusion Criteria

1. Adult Male over 19 years old and under 65 years old at screening.

2. Serum total testosterone level under 3.0 ng/mL at screening.

3. Subjects who had 18.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5 kg/m2 and a total body weight ≥ 55 kg.

   • Body Mass Index(BMI) = Weight(kg) / [Height(m)]2

4. Subjects without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years, except for hypogonadism.

5. Subjects who were deemed to be appropriate as study subjects in accordance with the screening results (laboratory tests, vital signs, ECG etc.).

6. Subjects who voluntarily signed an informed consent form approved by the Institutional Review Board(IRB) of each clinical study site and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content of the clinical trial.

7. Subjects who consent to the use of reliable contraception during the clinical trial. Subjects who have no plan of pregnancy and agree to not donate his sperm during the study period and up until 180 days after the last administration of investigational product.

8. Subjects with the ability and willingness to participate during the study period.

Read More

Exclusion Criteria

1. Subjects with a medical evidence or a history (excluding a hypogonadism, dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune disease.

   1-1. Subjects with a severe acute/chronic physical and mental conditions that can increase risk or interfere with the interpretation of the results of test.

   1-2. Subjects who have a androgen-dependent tumor(e.g., prostate cancer, male breast cancer).

   1-3. Subjects with hypercalcemia associated with malignant tumors.

   1-4. Subjects with or with a history of liver tumors.

   1-5. Subjects with bone metastasis of cancer.

   1-6. Subjects being treated for an enlarged prostate.

   1-7. Subjects who have severe alcohol and/or drug abuse history within a year from screening.

   1-8. Insulin-dependent diabetes mellitus or uncontrolled non-insulin- dependent diabetes mellitus.

2. Subjects with the following laboratory test results at screening:

   2-1. AST, ALT exceeding 2.5 times from the upper limit of normal.

   2-2. Total bilirubin exceeding 2.5 times from the upper limit of normal.

   2-3. Subjects had renal impairment(eGFR < 60 mL/min/1.73 m2)

   2-4. Positive results of virus/bacterial test and/or urine drug test at screening.

   2-5. Systolic blood pressure >150 mmHg or <90 mmHg and/or diastolic blood pressure >60 mmHg or >95 mmHg at sitting position.

3. History of regular alcohol consumption exceeding 210 g/week within 6 months prior to screening (1 drink (250 mL) of beer (5%) = 10 g, 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL of wine (12%) = 12 g).

4. Subjects who smoked more than 20 cigarettes per day within 6 months prior to screening.

5. Subjects who had been administered investigational product(s) from other clinical study or bioequivalence study within 180 days prior to the first dose of this study(except when subject have not taken investigational product(s)).

6. Subjects who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of drug-metabolizing enzymes within 30 days prior to the first dose of investigational product(s).

7. Subjects who had taken any contraindication drug(s)(Drug influencing the level of serum testosterone, modulating activity of testosterone and which have drug interaction) within 28 days prior to the first dose of investigational product(s).

8. Subjects who use of oral anticoagulants (with the exception of low-dose aspirin) within 28 days prior to the first dose of investigational product(s).

9. Subjects who use the testosterone pellet within 90 days prior to the first dose of investigational product(s).

10. Subjects who use of any injectable testosterone preparations within 28 days prior to the first dose of investigational product(s).

11. Subjects who use oral testosterone products within 7 days prior to the first dose of investigational product(s).

12. Subjects who use of supplements (e.g., saw palmetto, phytoestrogen, androstenedione, DHEA, niacin, fish oil etc.) prior to the first dose of investigational product(s).

13. Subjects who have hypersensitivity of investigational products and its components.

14. Subjects who donated whole blood within 60 days or blood components within 30 days prior to the first dose of the investigational product(s).

15. Subjects who were deemed inappropriate to participate in the study by the investigator.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Group 1	D309	1. Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.) 2. Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)
Group 2	CKD-845	1. Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.) 2. Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)
Group 1	CKD-845	1. Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.) 2. Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)
Group 2	D309	1. Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.) 2. Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)

Primary Outcome Measures

Name	Time	Method
Baseline corrected AUCt of CKD-845	up to 70 days	AUCt: Area under the concentration-time curve from time zero to time
Baseline corrected Cmax of CKD-845	up to 70 days	Cmax: Maximum plasma concentration of the drug

Secondary Outcome Measures

Name	Time	Method
Baseline corrected Tmax of CKD-845	up to 70 days	Tmax: Time to maximum plasma concentration
Baseline corrected t1/2 of CKD-845	up to 70 days	t1/2: Terminal elimination half-life
Baseline corrected AUCinf of CKD-845	up to 70 days	AUCinf: Area under the concentration-time curve from zero up to infinity

Trial Locations

Locations (1)

Jeonbuk University Hospital; 🇰🇷 Jeonju, Jeonbuk, Korea, Republic of